Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma

Abstract

These results indicate that a multifaceted assessment of cognition, QOL, and patient function is practical for brain tumor patients in clinical trials and can provide information regarding the relative risks versus benefits of new treatment regimens that supplements the information from the usual clinical variables.